Please check out our website www.lowcarbdiabetic.co.uk We created and maintain this site without any help from anyone else. In doing so, we do not receive direct or indirect funding from anyone. We do not accept money or favours to manipulate the evidence in any way. Please visit our Low Carb food and recipe blog www.lowcarbdietsandrecipes.blogspot.com
Wednesday, 29 January 2014
SGLT2 Inhibitors May Up Glucose Production
Although they increase the amount of blood sugar dumped into the urine, the newest class of diabetes drugs appears to increase endogenous glucose production, two studies found.
Sodium glucose cotransporter 2 (SGLT2) inhibitors increased endogenous glucose and raised levels of the hormone glucagon, which prompts the body to produce glucose, according to the studies in theJournal of Clinical Investigation.
This is "clearly a surprising finding that would be considered a paradoxical response," William Cefalu, MD, of Pennington Biomedical Research Center in Louisiana, said in an accompanying editorial.
They had mixed-meal testing with a double tracer technique at baseline, after a single first dose of the drug, and then after 28 days of daily therapy.
By the end of the study, the researchers found that the drug was also effective at excreting blood glucose through the urine, but, as with dapagliflozin, both endogenous glucose production and glucagon levels were increased.
They wrote that the rise in endogenous glucose production exactly balanced the glucose lost through the urine, suggesting the glycosuria "results in a compensatory increase in endogenous glucose release ... as a consequence of lower glucose and insulin levels and higher glucagon levels."
In the editorial, Cefalu said it "would be expected that SGLT2 inhibition would decrease endogenous glucose production."
"The observation that neither dapagliflozin nor empagliflozin reduced endogenous glucose production despite the lowering of blood glucose is clearly a surprising finding that would be considered a paradoxical response," he wrote.
He noted that if the findings are replicated, clinicians may want to use SGLT2 inhibitors together with incretin therapies, which have effects on glucagon and could attenuate the increase in endogenous glucose production, although further metabolic studies are needed.